BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune Checkpoint Sensitivity in BRAFV600E -mutant...

Area of Science:

• Neuro-oncology
• Cancer immunology
• Molecular oncology

Background:

• BRAF plus MEK inhibition (BRAFi+MEKi) is a targeted therapy for BRAFV600E-mutant gliomas.
• Resistance to BRAFi+MEKi leads to tumor progression and poor outcomes.
• Mechanisms underlying BRAFi+MEKi resistance in gliomas are not fully understood.

Purpose of the Study:

• To investigate the mechanisms of BRAFi+MEKi resistance in BRAFV600E-mutant gliomas.
• To explore novel therapeutic strategies to overcome BRAFi+MEKi resistance.
• To evaluate combination therapies involving BRAFi+MEKi and immune checkpoint inhibitors.

Main Methods:

• Utilized novel mouse models and patient-derived glioma materials.
• Analyzed cell state transitions and glial differentiation trajectories.
• Assessed PD-L1 expression, interferon response signatures, and T cell infiltration.
• Investigated combination therapy of BRAFi+MEKi with immune checkpoint inhibition.

Main Results:

• BRAFi+MEKi induces glioma cell plasticity, leading to astrocyte- and oligodendrocyte-like states.
• Upregulation of PD-L1 in oligodendrocyte-like cells correlates with tumor immune evasion.
• BRAFi+MEKi treatment activates interferon response and suppresses T cells.
• Combination therapy of BRAFi+MEKi with immune checkpoint inhibition significantly enhances survival in mice.
• Combination therapy reinvigorates T cells and outperforms monotherapy or sequential treatments.

Conclusions:

• Targeting glioma plasticity is a promising strategy to overcome BRAFi+MEKi resistance.
• Combination of BRAFi+MEKi with immune checkpoint inhibition offers a potent therapeutic approach for BRAFV600E-mutant gliomas.
• Elevated PD-L1 in BRAF-mutant glioblastoma supports PD-1 inhibition in patients.